Infectious Diseases
- Ref-No.Technology
- 01-01011Biphasic, copolymeric, stretchable membrane and bioreactor for investigating cells at the air liquid interface (ALI)
- 01-01024
CRISPR/Cas13-based approach for the treatment of viral diseases caused by RNA viruses
- 01-01030
Rapid quantitation of virus-neutralizing antibodies in biosamples - a novel BSL1 approach based on virus-like particles (VLPs)
- 02-00303Novel Myxopyronin Analogues and Myxopyronin Genecluster for Mutasynthesis
- 02-00311Cystobactamids – novel antibacterials against gram-negative pathogens
- 02-00315Novel Chelocardin Derivatives – resistance breaking atypical tetracyclines with broad-spectrum antibiotic activity
- 02-00316Innovative Inhibitors of Pseudomonas Pathogenicity
- 02-00324Innovative DOTA-Linkers for Bacterial Targeting
- 02-00328Determination of Biofilm Dynamics via Impedance
- 02-00329
PADFEX- A device for direct pathogen detection in filtered expirates
- 02-00332Novel inhibitors of Pseudomonas aeruginosa LecB
- 02-00337Novel labyrinthopeptins as anti-viral agents
- 02-00351Increased Availability and Efficacy of Aminoglycosides
- 02-00353
High-throughput Screening for anti-herpesviridae Drugs
- 02-00354Highly active Chlorotonil A Derivatives for the treatment of Malaria
- 02-00368Bivalent LecA Inhibitors Targeting Biofilm Formation of Pseudomonas aeruginosa
- 02-00373Highly potent small molecules prevent tissue damage following S. aureus infection by inhibiting α-hemolysin
- 02-00374
Phytosphingosine Derivatives as Adjuvants in Immune Stimulation
- 02-00375CRISPRdetect – multiplexed RNA detection with reprogrammed tracrRNAs
- 02-00376
Overcoming resistance - Innovative broad-spectrum inhibitors of Metallo- β-lactamases
- 02-00378
Overcoming resistance - Novel inhibitors of virulence factor LasB of Pseudomonas aeruginosa
- 02-00387
Novel Darobactin Derivatives - highly active antibacterials against gram-negative bacteria
- 02-00393
REVERSE EPITOMICS BASED IDENTIFICATION OF ANTIGENIC PATCHES FOR IMMUNOGENIC COMPOSITIONS
- 02-00395
Novel derivates of griselimycin and their use as antimycobacterial agents
- 02-00396
Novel lectin-targeting conjugates for treatment or diagnosis of bacterial infections
- 02-00397
Novel vaccine vector platform for safe and effective immunization using a replication-deficient murine cytomegalovirus (MCMV)
- 02-00402
Novel Inhibitors of Cytomegalovirus
- 02-00405
TRSbait – RNA-mimicry of viral transcription regulator as
antiviral drug - 02-00413
Rapid Detection of Shiga toxin producing E.coli (STEC)
- 03-00553
Human TCR constructs for adoptive cell therapy of cancer
- 10-00026Novel Benzothiazinones, potent Tuberculosis antibiotics
- 10-00087Jagaricin – a novel antifungal natural compound
- 10-00107Barnesins – novel natural small molecules as highly specific cysteine protease inhibitors
- 14-00020
Anti-inflammatory, LPS-neutralizing and anti-bacterial agent against sepsis and other severe bacterial infections
- 14-00020bSALP peptides are potent broad-spectrum anti-viral agents
- 14-00097
Anti-inflammatory, anti-bacterial agent for treatment of Atopic Dermatitis
- 14-00097
Antimicrobial, endotoxine-neutralizing and anti-inflammatory agent for wound healing and treatment of bacterial skin and soft-tissue infections
- 14-00098
Targeting host lipid homeostasis to augment anti-mycobacterial treatment
- 14-00128
Blood-based tuberculosis precision medicine: transcriptomic model shortens therapy duration
- 14-00169
Blood-based tuberculosis precision medicine: transcriptomic model predicts treatment response
- 14-00176
Efficient, adjuvant-free mucosal vaccination via IgA feedback loop
- 15-00461
The physiological breast-milk proteins S100A8 and S100A9 promote an eubiotic gut state in infants
- 18-00050
Lonafarnib inhibits cell entry of Human Respiratory Syncytial Virus (hRSV)
- 18-00052
Broadly neutralizing antibodies against hepatitis E virus (HEV)
- 22-00020Bispecific antibodies for cell-type-specific TNF inhibition
- 32-00135
Novel broad spectrum SARS-CoV-2 Vaccine Gene
- 43-00016
SARSeq: Multiplexed, parallel detection of SARS-CoV2 variants and other viruses in high-throughput
- 44-00013
Keratinophile photosensitizers for safe and rapid treatment of onychomycosis